High-dose calcitriol, docetaxel and zoledronic acid in patients with castration-resistant prostate cancer: A phase II study

Urologia Internationalis

Volumn 90, Issue 1, 2013, Pages 56-61

  Shamseddine, Ali ^a   Farhat, Fadi S ^b   Elias, Elias ^a   Khauli, Raja B ^a   Saleh, Ahmad ^a   Bulbul, Mohammad A ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b Hammoud Hospital   (Lebanon)

Author keywords

Calcitriol; Castration resistant prostate cancer; Docetaxel; Phase II study; Zoledronic acid

Indexed keywords

CALCITRIOL; DOCETAXEL; PROSTATE SPECIFIC ANTIGEN; ZOLEDRONIC ACID;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BACKACHE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; COLITIS; CONSTIPATION; CYSTITIS; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EDEMA; EPISTAXIS; ESOPHAGITIS; FEVER; HEARING IMPAIRMENT; HEMATURIA; HIP PAIN; HUMAN; LEUKOPENIA; LUNG EMBOLISM; MALE; MENINGITIS; MULTIPLE CYCLE TREATMENT; NAUSEA; ONYCHOLYSIS; ORCHIECTOMY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; POLYNEUROPATHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATECTOMY; SIDE EFFECT; SURVIVAL TIME; TASTE DISORDER; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT RESPONSE; URINE INCONTINENCE; VOMITING; WEAKNESS; WEIGHT REDUCTION;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CALCITRIOL; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; HUMANS; IMIDAZOLES; INFUSIONS, INTRAVENOUS; KALLIKREINS; KAPLAN-MEIER ESTIMATE; LEBANON; MALE; MIDDLE AGED; ORCHIECTOMY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TAXOIDS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84872619910     PISSN: 00421138     EISSN: 14230399     Source Type: Journal    
DOI: 10.1159/000343780     Document Type: Article

References (30)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Chodak GW, Keane T, Klotz L: Critical evaluation of hormonal therapy for carcinoma ofthe prostate. Urology 2002; 60: 201-208.
3. Shelley M, Harrison C, Coles B, Staffurth J, Wilt TJ, Mason MD: Chemotherapy for hormone- refractory prostate cancer. Cochrane Database Syst Rev 2006;4:CD005247.
4. Muthuramalingam SR, Patel K, Protheroe A: Management of patients with hormone refractory prostate cancer. Clin Oncol (R Coll Radiol) 2004; 16: 505-516.
5. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-1512.
6. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-1520.
7. Johnson CS, Muindi JR, Hershberger PA, Trump DL: The antitumor efficacy of calcitriol: Preclinical studies. Anticancer Res 2006; 26: 2543-2549.
8. Beer TM, Eilers KM, Garzotto M, Egorin MJ, Lowe BA, Henner WD: Weekly high-dose calcitriol and docetaxel in metastatic androgen- independent prostate cancer. J Clin Oncol 2003; 21: 123-128.
9. Nayyar R, Sharma N, Gupta NP: Docetaxelbased chemotherapy with zoledronic acid and prednisone in hormone refractory prostate cancer: Factors predicting response and survival. Int J Urol 2009; 16: 726-731.
10. Di Lorenzo G, Autorino R, Figg WD, De Placido S: Hormone-refractory prostatecancer: Where are we going? Drugs 2007; 67:1109-1124.
11. Bhandari MS, Petrylak DP, Hussain M: Clinicaltrials in metastatic prostate cancer - hasthere been real progress in the past decade? Eur J Cancer 2005; 41: 941-953.
12. De Dosso S, Berthold DR: Docetaxel in the management of prostate cancer: Current standard of care and future directions. Expert Opin Pharmacother 2008; 9: 1969-1979.
13. Picus J, Schultz M: Docetaxel (Taxotere) asmonotherapy in the treatment of hormonerefractory prostate cancer: Preliminary results.Semin Oncol 1999; 26: 14-18.
14. Friedland D, Cohen J, Miller R Jr, Voloshin M, Gluckman R, Lembersky B, Zidar B, Keating M, Reilly N, Dimitt B: A phase II trialof docetaxel (Taxotere) in hormone-refractoryprostate cancer: Correlation of antitumoreffect to phosphorylation of Bcl-2.Semin Oncol 1999; 26(5 suppl 17): 19-23.
15. Hainsworth JD: Practical aspects of weekly docetaxel administration schedules. Oncologist2004; 9: 538-545.
16. Berry W, Dakhil S, Gregurich MA, Asmar L: Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic,metastatic carcinoma of the prostate. SeminOncol 2001; 28: 8-15.
17. Petrioli R, Pozzessere D, Messinese S, Sabatino M, Di Palma T, Marsili S, Correale P, Manganelli A, Salvestrini F, Francini G: Weekly low-dose docetaxel in advanced hormone- resistant prostate cancer patients previously exposed to chemotherapy. Oncology 2003; 64: 300-305.
18. Kojima T, Shimazui T, Onozawa M, Tsukamoto S, Hinotsu S, Miyanaga N, Hattori K, Kawai K, Akaza H: Weekly administration of docetaxel in patients with hormone-refractory prostate cancer: A pilot study on Japanese patients. Jpn J Clin Oncol 2004; 34: 137-141.
19. Skowronski RJ, Peehl DM, Feldman D: Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology 1993; 132: 1952-1960.
20. Krishnan AV, Moreno J, Nonn L, Swami S, Peehl DM, Feldman D: Calcitriol as a chemopreventive and therapeutic agent in prostate cancer: Role of anti-inflammatory activity. J Bone Miner Res 2007; 22(suppl 2):V74-V80.
21. Getzenberg RH, Light BW, Lapco PE, Konety BR, Nangia AK, Acierno JS, Dhir R, Shurin Z, Day RS, Trump DL, Johnson CS: Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system. Urology 1997; 50: 999-1006.
22. Ting HJ, Hsu J, Bao BY, Lee YF: Docetaxelinduced growth inhibition and apoptosis in androgen independent prostate cancer cells are enhanced by 1alpha,25-dihydroxyvitamin D3. Cancer Lett 2007; 247: 122-129.
23. Beer TM, Ryan CW, Venner PM, Petrylak DP, Chatta GS, Ruether JD, Redfern CH, Fehrenbacher L, Saleh MN, Waterhouse DM, Carducci MA, Vicario D, Dreicer R, HiganoCS, Ahmann FR, Chi KN, Henner WD,Arroyo A, Clow FW: Double-blinded randomizedstudy of high-dose calcitriol plusdocetaxel compared with placebo plusdocetaxel in androgen-independent prostatecancer: A report from the ASCENT Investigators.J Clin Oncol 2007; 25: 669-674.
24. Saad F, Gleason DM, Murray R, TchekmedyianS, Venner P, Lacombe L, Chin JL, VinholesJJ, Goas JA, Zheng M: Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004; 96: 879-882.
25. Morris MJ, Scher HI: Clinical approaches toosseous metastases in prostate cancer. Oncologist 2003; 8: 161-173.
26. Scher HI, Jia X, Chi K, de Wit R, Berry WR, Albers P, Henick B, Waterhouse D, Ruether DJ, Rosen PJ, Meluch AA, Nordquist LT, Venner PM, Heidenreich A, Chu L, Heller G: Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. J Clin Oncol 2011; 29: 2191-2198.
27. Kattan JG, Farhat FS, Chahine GY, Nasr FL, Moukadem WT, Younes FC, Yazbeck NJ, Ghosn MG: Weekly docetaxel, zoledronic acid and estramustine in hormone-refractory prostate cancer (HRPC). Invest New Drugs 2008; 26: 75-79.
28. Ross RW, Beer TM, Jacobus S, Bubley GJ, Taplin ME, Ryan CW, Huang J, Oh WK: A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractoryprostate cancer who are refractory to docetaxel. Cancer 2008; 112: 521-526.
29. Culine S, El Demery M, Lamy PJ, Iborra F, Avances C, Pinguet F: Docetaxel and cisplatin in patients with metastatic androgen independent prostate cancer and circulating neuroendocrine markers. J Urol 2007; 178: 844-848, discussion 848.
30. Di Lorenzo G, Autorino R, Perdona S, De Laurentiis M, D'Armiento M, Cancello G, Mirone V, Imbimbo C, Longo N, Altieri V, Tortora G, Figg WD, De Placido S: Docet axel, vinorelbine, and zoledronic acid as first-line treatment in patients with hormone refractory prostate cancer: A phase II study. Eur Urol 2007; 52: 1020-1027.